Site
Search results
An Important Message About SPRAVATO® (esketamine) CIII Nasal Spray
Aug 22, 2019 TITUSVILLE, NJ An Important Message About SPRAVATO® (esketamine) CIII Nasal Spray ...
An Important Message About SPRAVATO (esketamine) CIII Nasal Spray
Jun 19, 2019 Titusville, NJ An Important Message About SPRAVATO TM (esketamine) CIII Nasal Spray ...
Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment- Resistant Depression
Sep 04, 2018 TITUSVILLE, NJ Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment- Resistant Depression ...
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
Sep 21, 2018 TITUSVILLE, N.J. Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression ...
FDA Advisory Committee Recommends Approval of SPRAVATOTM (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression
Feb 12, 2019 TITUSVILLE, N.J. FDA Advisory Committee Recommends Approval of SPRAVATOTM (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression ...
Esketamine Phase 2 Data Published in JAMA Psychiatry Showed Significant Improvement of Depressive Symptoms in People with Treatment-Resistant Depression
Dec 28, 2017 TITUSVILLE, NJ Esketamine Phase 2 Data Published in JAMA Psychiatry Showed Significant Improvement of Depressive Symptoms in People with Treatment-Resistant Depression ...
New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression
May 05, 2018 Titusville, NJ New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression ...
Janssen Announces U.S. FDA Approval of SPRAVATO (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief
Mar 05, 2019 TITUSVILLE, N.J. Janssen Announces U.S. FDA Approval of SPRAVATO TM (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief ...
Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
Aug 03, 2020 TITUSVILLE, N.J. Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior ...
New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)
May 21, 2019 NEW ORLEANS, LA New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD) 1 ...